Sai Life Sciences Ltd.
SAILIFEHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
7 transcript(s)/analyst meet(s) served; 4 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 7 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20250212 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250521 | 2025-03-31 | yes | |
| COVER_LETTER | 20250818 | 2025-06-30 | no | |
| COVER_LETTER | 20251114 | 2025-09-30 | no | |
| COVER_LETTER | 20260213 | 2025-12-31 | no | |
| COVER_LETTER | 20260521 | 2026-03-31 | no | |
| TRANSCRIPT | 20260812 | 2026-06-30 | yes |
SAILIFE
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,594.90 |
| 52-week range | 795.0 – 1675.4 |
| Return 1M | 9.58% |
| Return 3M | 30.59% |
| Return 1Y | 78.81% |
| Return 3Y | not reported for this period |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 554.00 |
| Other income | 4.00 |
| Total income | 558.00 |
| Cost of materials consumed | 178.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -33.00 |
| Employee benefit expense | 180.00 |
| Finance costs | 8.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.35 | -0.00 |
| institutions foreign | 0.20 | -0.02 |
| institutions domestic | 0.33 | 0.01 |
| mutual funds | 0.29 | 0.02 |
| public | 0.65 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| COVER_LETTER | 2026-03-31 | 4 |
| TRANSCRIPT | 2026-06-30 | 3 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2024-12-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|
| Revenue from operations | 440.00 | 496.00 | 537.00 | 556.00 | 602.00 | 554.00 |
| Other income | 9.00 | 10.00 | 15.00 | 8.00 | 16.00 | 4.00 |
| Total income | 449.00 | 506.00 | 553.00 | 565.00 | 618.00 | 558.00 |
| Cost of materials consumed | 122.00 | 160.00 | 204.00 | 114.00 | 159.00 | 178.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | -1.00 | -18.00 | -63.00 | 14.00 | 3.00 | -33.00 |
| Employee benefit expense | 133.00 | 161.00 | 163.00 | 173.00 | 187.00 | 180.00 |
| Finance costs | 23.00 | 12.00 | 9.00 | 10.00 | 8.00 | 8.00 |
| Depreciation and amortisation | 34.00 | 38.00 | 40.00 | 44.00 | 45.00 | 46.00 |
| Other expenses | 66.00 | 74.00 | 89.00 | 68.00 | 77.00 | 81.00 |
| Total expenses | 377.00 | 426.00 | 441.00 | 422.00 | 479.00 | 460.00 |
| Profit before exceptional items and tax | 72.00 | 81.00 | 112.00 | 142.00 | 139.00 | 98.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | -8.00 | 0.00 | 0.00 |
| Profit before tax | 72.00 | 81.00 | 112.00 | 134.00 | 139.00 | 98.00 |
| Current tax | 10.00 | 14.00 | 30.00 | 31.00 | 13.00 | 20.00 |
| Deferred tax | 8.00 | 6.00 | -1.00 | 2.00 | 22.00 | 5.00 |
| Tax expense | 18.00 | 20.00 | 28.00 | 34.00 | 35.00 | 25.00 |
| Profit for the period | 54.00 | 60.00 | 84.00 | 100.00 | 104.00 | 73.00 |
| Profit attributable to owners | 0.00 | — | 0.00 | 0.00 | — | 0.00 |
| Profit attributable to non-controlling interests | 0.00 | — | 0.00 | 0.00 | — | 0.00 |
| Other comprehensive income | -4.00 | 2.00 | -14.00 | 1.00 | -9.00 | 20.00 |
| Total comprehensive income | 50.00 | 62.00 | 70.00 | 101.00 | 95.00 | 93.00 |
| Earnings per share, basic | 2.89 | 2.90 | 4.01 | 4.77 | 4.93 | 3.46 |
| Earnings per share, diluted | 2.84 | 2.83 | 3.93 | 4.71 | 4.87 | 3.42 |
Annual results, as filed
| Line | 2026-03-31 |
|---|---|
| Revenue from operations | 2,192.00 |
| Other income | 49.00 |
| Total income | 2,242.00 |
| Cost of materials consumed | 578.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | -7.00 |
| Employee benefit expense | 683.00 |
| Finance costs | 39.00 |
| Depreciation and amortisation | 167.00 |
| Other expenses | 307.00 |
| Total expenses | 1,767.00 |
| Profit before exceptional items and tax | 474.00 |
| Exceptional items | -8.00 |
| Profit before tax | 466.00 |
| Current tax | 88.00 |
| Deferred tax | 29.00 |
| Tax expense | 117.00 |
| Profit for the period | 349.00 |
| Other comprehensive income | -21.00 |
| Total comprehensive income | 328.00 |
| Earnings per share, basic | 16.63 |
| Earnings per share, diluted | 16.43 |
Balance sheet, as filed
| Line | 2025-09-30 | 2026-03-31 |
|---|---|---|
| Total assets | 3,332.00 | 3,626.00 |
| Non-current assets | 1,842.00 | 2,216.00 |
| Current assets | 1,489.00 | 1,411.00 |
| Property, plant and equipment | 1,613.00 | 1,809.00 |
| Capital work-in-progress | 115.00 | 270.00 |
| Goodwill | 0.00 | 0.00 |
| Other intangible assets | 9.00 | 6.00 |
| Inventories | 122.00 | 151.00 |
| Trade receivables | 492.00 | 374.00 |
| Cash and cash equivalents | 208.00 | 82.00 |
| Total equity and liabilities | 3,332.00 | 3,626.00 |
| Equity | 2,270.00 | 2,484.00 |
| Equity share capital | 21.00 | 21.00 |
| Other equity | 2,249.00 | 2,463.00 |
| Total liabilities | 1,062.00 | 1,142.00 |
| Non-current liabilities | 286.00 | 309.00 |
| Current liabilities | 775.00 | 834.00 |
| Borrowings, non-current | 0.00 | 21.00 |
| Borrowings, current | 215.00 | 75.00 |
| Trade payables | 245.00 | 285.00 |
Cash flow, as filed
| Line | 2025-09-30 | 2026-03-31 |
|---|---|---|
| Net cash from operating activities | 93.00 | 509.00 |
| Net cash from investing activities | -11.00 | -395.00 |
| Net cash from financing activities | 32.00 | -124.00 |
| Purchase of property, plant and equipment | 248.00 | 593.00 |
| Net increase in cash | 117.00 | -9.00 |
| con:CFO.BEFORE_TAX | 122.00 | 548.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 29.00 | 39.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 2.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 1.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2024-12-18 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 35.24 | 35.24 | 35.17 | 35.15 | 0.35 | 0.35 | 0.35 | 0.35 |
| Domestic institutions | 5.61 | 11.95 | 13.26 | 21.64 | 0.30 | 0.31 | 0.32 | 0.33 |
| Mutual funds | — | — | — | 18.73 | 0.26 | 0.28 | 0.28 | 0.29 |
| Insurance companies | 0.53 | 1.06 | 1.31 | 2.50 | 0.03 | 0.03 | 0.03 | 0.03 |
| Foreign institutions | 7.64 | 11.72 | 12.36 | 14.58 | 0.23 | 0.21 | 0.21 | 0.20 |
| Government | — | — | — | — | — | — | — | 0.00 |
| Public | 64.76 | 64.76 | 64.83 | 64.85 | 0.65 | 0.65 | 0.65 | 0.65 |
| Non-institutional | 51.52 | 41.09 | 39.21 | 28.64 | 0.13 | 0.12 | 0.13 | 0.13 |
| Shares outstanding | 207989529 | 207989529 | 208414389 | 208545302 | 209749267 | 211231216 | 211779234 | 212286016 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-08-12 | Q1FY27 | LIMITED | Read the call |
| 2025-05-21 | Q4FY25 | Read the call | |
| 2025-02-12 | Q3FY25 | AND CHIEF EXECUTIVE OFFICER | Read the call |
Some earlier announcements under this heading are covering letters only — no transcript was attached.
What they said about it, quarter by quarter
| Topic | Q1FY27 | Q3FY25 | Q4FY25 |
|---|---|---|---|
| Capex | So you are entering a much heavier investment cycle with up to INR1,300 crores of capex, which includes a greenfield for peptides. | Capital expenditure for the 9 months ended December 24 was 300 crores. | We ended the year with a capex spend of INR408 crores, in line with our investment plan to expand manufacturing capacity and strengthen our discovery … |
| Capital allocation | Historically have we seen those orders post-acquisition, does that project necessarily stay with us? | Just to give you a perspective, Binay, a little bit about what we have done so far is, we have completed some land acquisition in the last quarter. | — |
| Costs | — | — | Looking at the broad industry, the global CRDMO sector continues to see strong momentum, increasing emphasis on supply chain resilience, cost pressure… |
| Debt and cash | — | Finance costs remain relatively stable at 23 crores for Q3 FY '25 compared to 23 crores in the same quarter last year, indicating effective debt manag… | This is seen in the working capital data that stood at 117 days, showing efficient cash and inventory management. |
| Demand | The clear message we are picking up is that these new companies will be built with even leaner in-house capabilities, which should continue to support… | We supply over 31 commercial molecules and have a strong development pipeline Sai Life Sciences Limited February 07, 2025 of life-saving medicines acr… | As demand rises for peptide-based and other emerging modalities, there's investment positions as well to cater to next-generation therapeutics. |
| Guidance | As we have discussed in the previous earnings call, we expect a stronger H2 with planned capacity expansion going live in the second half of the year. | A special thanks to our bankers, legal counsels and all stakeholders who played a critical role in guiding us through this process. | We are pleased to see our profitability profile moving closer to a long-term guidance of 28% to 30% EBITDA margin. |
| Margin | — | Our EBITDA grew by 19% year-over-year, with a margin expansion of 110 basis points, while the PAT grew by 29% year-over-year, supported by operational… | EBITDA grew by 42% with margin expansion of 458 basis points. |
| People | — | Employee cost of the period increased by 9%, moving from 122 crores in Q3 FY '24 to 133 crores in Q3 FY '25, aligning with the increased billable head… | And capacity utilisation is fairly high, and we're seeing good visibility in the business. |
| Pricing | — | The other one is, can you comment about the pricing of FTs? | Are you seeing any pricing margins there? |
| Revenue growth | — | Again, Siva will dwell deeper into financials, but I am just stating the top line numbers. | This reflects a 16% year-on-year growth as compared to INR1,465 crores in FY24. This growth was driven by sustained momentum across both our businesse… |